Please assess the completion status of the following clinical trial:

Trial Title: Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females patients, aged \>3 years and \< 30 years;~* Newly diagnosed of GBM, DIPG, diffuse brainstem glioma, diffuse spinal glioma, bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma;~* Patients undergone either surgery or biopsy only;~* No prior chemotherapy and/or radiotherapy;~* Life expectancy ≥ 4 weeks;~* Karnofsky/Lansky ≥ 40 %;~* Written informed consent obtained from the patient/parents or legal representative;~* Adequate hematological function (leucocyte ≥ 2.0 x 10\^9/l -Hemoglobin ≥ 10 g/dl - platelet ≥ 50 x 10\^9 /l);~* Adequate liver function (total bilirubin ≤ 2.5 x ULN - ALT/AST ≤ 5.0 x ULN);~* Adequate renal function (serum creatinine ≤ 1.5 x ULN);~* Adherence to trial treatment and compliance with the protocol~Exclusion Criteria:~* Any disease or condition that contraindicates the use of the study drug (es. serious mental retardation, brain palsy, congenital syndrome, cardiomyopathy)~* Prior anti-cancer therapy~* Pregnancy or breastfeeding~* Non adequate contraception

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Doxorubicin (Type: EXPERIMENTAL): Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day.

Based on this trial design, predict the completion outcome and termination type (if applicable).